tbuckley/cabot-search huggingface dataset:
Natural History of Left Ventricular Mechanics in Transplanted Hearts
Authors: Mackram F. Eleid, Giuseppe Caracciolo, Eun Joo Cho, Robert L. Scott, D. Eric Steidley, Susan Wilansky, Francisco A. Arabia, Bijoy K. Khandheria, Partho P. Sengupta
Journal: JACC. Cardiovascular imaging (2010)
Cardiomyocyte Injury Assessed by a Highly Sensitive Troponin Assay and Sudden Cardiac Death in the Community
Authors: Ayman A. Hussein, John S. Gottdiener, Traci M. Bartz, Nona Sotoodehnia, Christopher deFilippi, Timm Dickfeld, Rajat Deo, David Siscovick, Phyllis K. Stein, Donald Lloyd-Jones
Journal: Journal of the American College of Cardiology (2013)
Abstract 2053: Cardiac Arrest and Resuscitation Increases Nos3-Dependent Formation of Circulating Nitrosylhemoglobin (HbNO)
Authors: David G Beiser, Gerasim Orbelyan, Karel Chalupsky, Kimm Hamann, Elizabeth M McNally, Terry L Vanden Hoek
Journal: Circulation (2008)

OBJECTIVE: To characterize the enzyme-mediated nitrosylhemoglobin production following cardiac arrest. METHODS: Adult female wildtype (WT, n=5) and NOS3−/− (n=8) mice were anesthetized, intubated, ventilated, and instrumented with intravascular catheters. Arrest was induced with intravenous KCl. After 8 minutes of untreated arrest, chest compression and ventilations were performed. Hemodynamics were monitored for up to 120 minutes following return of spontaneous circulation (ROSC). Electron paramagnetic resonance spectroscopy was used to measure nitrosylhemoglobin (HbNO) in whole blood samples obtained from animals (WT and NOS3−/−, n=4 per time point) sacrificed at: baseline (BL), following 8 (CA8) or 20 (CA20) minutes of untreated arrest and at 60 (R60) or 120 (R120) minutes following ROSC. Heart tissue total-NOS3 and phospho-NOS3 were assayed by Western blot. RESULTS: At BL, NOS3−/−animals displayed higher maximum left-ventricular pressure (LVPmax) than WT animals (113.3 ± 13.19 mmHg vs. 86.8 ± 4.48 mmHg, p&lt;0.05). In the R120 group, ROSC was achieved in 4 of 5 (80%) WT and 4 of 8 (50%) NOS3−/− animals. Following ROSC, NOS3−/−animals displayed lower LVPmax (51.97 ± 7.429 vs. 66.95 ± 4.394 mmHg, p&lt;0.05) and left ventricular stroke work (132.5 ± 26.28 mmHg·μL vs. 456.5 ± 128.9 mmHg·μL, p&lt;0.05) than WT. NOS3−/− animals displayed significantly higher left-ventricular relaxation time constants (tau = 25.82 ± 6.471 ms vs. 15.45 ± 2.223 ms, p&lt;0.05) at R120. At BL, whole blood HbNO concentrations were similar in WT and NOS3−/− animals (0.75 ± 0.10 μM vs. 0.86 ± 0.11 μM, p=0.46). In WT animals, HbNO concentrations increased during untreated arrest at CA20 (1.42 ± 0.19 μM, p&lt;0.05) and following resuscitation at R120 (1.66 ± 0.25 μM, p&lt;0.05) relative to BL. HbNO concentrations were lower in NOS3−/− animals as compared to WT at all time points following cardiac arrest (p&lt; 0.05). Heart tissue from WT animals displayed increased levels of heart tissue total-NOS3 and phospho-NOS3 at R60. CONCLUSIONS: Circulating HbNO increases following cardiac arrest and resuscitation. Such increases appear to be NOS3-dependent and are associated with improved cardiovascular function.
Lower blood pressure and the risk of recurrent stroke in patients with chronic kidney disease: results of the PROGRESS trial
Authors: T. Ninomiya, Vlado Perkovic, Martin P. Gallagher, Meg Jardine, Alan Cass, Hisatomi Arima, Craig S. Anderson, B Neal, Mark Woodward, T. Omae, Stephen MacMahon, J. P. Chalmers
Journal: Kidney International (2008)
Analyzing the Biology on the System Level
Authors: Wei Tong
Journal: Genomics Proteomics & Bioinformatics (2004)

Abstract Although various genome projects have provided us enormous static sequence information, understanding of the sophisticated biology continues to require integrating the computational modeling, system analysis, technology development for experiments, and quantitative experiments all together to analyze the biology architecture on various levels, which is just the origin of systems biology subject. This review discusses the object, its characteristics, and research attentions in systems biology, and summarizes the analysis methods, experimental technologies, research developments, and so on in the four key fields of systems biology—systemic structures, dynamics, control methods, and design principles.
Activity of bevacizumab at the time of surgery after 6 weeks of preoperative cessation.
Authors: Patrick Starlinger, Lejla Alidzanovic, Dominic Schauer, Thomas Maier, Silvia Sommerfeldt, Beata Herberger, Dietmar Tamandl, Birgit Gruenberger, Thomas Gruenberger, Christine Brostjan
Journal: Journal of Clinical Oncology (2012)

455 Background: The use of bevacizumab (BV), a monoclonal antibody against VEGF, and combination chemotherapy (CTx) together with an increase in hepatic resection has improved the outcome of colorectal cancer (CRC) patients with liver metastasis. However, despite the frequent use of BV, its accurate timing prior to liver resection to avoid surgical complications and to allow for hepatic regeneration remains discussed controversially. In this context, it remains unclear to which extent VEGF is complexed by BV at the time of surgery. Methods: Fifty CRC patients with liver metastases, potentially curable by resection, were included. Patients received neoadjuvant CTx either with or without concomitant biweekly BV. The last cycle of therapy did not include BV, resulting in 5 weeks between the last administration of BV and surgery. Plasma and wound fluid subcutaneously and intra-abdominally were obtained perioperatively. Immunoprecipitation was applied to determine the proportion of BV-bound VEGF. Results: 42 patients underwent surgery. Median time of BV cessation was 5-6 weeks. No increased perioperative complications in this BV treated patients were observed (patients without complications: 59 % of BV + CTx patients versus 50 % in CTx patients). At the time of surgery, the majority of plasma VEGF was inactivated by BV. In wound fluid, the actual site of wound healing and hepatic regeneration, VEGF was remarkably low and also complexed by BV. This resulted in a highly significant reduction of unbound/biologically active VEGF levels in plasma and wound fluid of BV treated patients (both: P &lt; 0.001). Conclusions: These data documents that, after the clinical standard cessation time point of 5-6 weeks, BV is still fully active and binds to the majority of circulating and local (wound fluid) VEGF. Despite the potent VEGF inactivation, at the time of liver resection no substantial increase in perioperative morbidity after neoadjuvant BV therapy has been documented in our study and the current literature.
Abstract 17495: Achievement of Secondary Prevention Performance Measures in Patients with Coronary Artery Disease in Teaching and Non-Teaching Hospitals: Results from the Get With The Guidelines CAD Program
Authors: Lori M Tam, Gregg C Fonarow, Deepak L Bhatt, Maria V Grau-Sepulveda, Adrian F Hernandez, Eric D Peterson, Lee H Schwamm, Robert P Giugliano
Journal: Circulation (2010)

Background: Guideline-recommended therapies improve clinical outcomes in patients with non-ST-elevation acute coronary syndrome, and previous studies suggest that academic hospitals are more likely...
Measles in Italy, July 2009 to September 2010
Authors: A Filia, A Tavilla, A Bella, F Magurano, F Ansaldi, M Chironna, L Nicoletti, G Palù, S Iannazzo, S Declich, M C Rota
Journal: Eurosurveillance (2011)

Outbreaks of measles continue to occur in Italy, as in other European countries. We present here details of cases reported through the Italian enhanced measles surveillance system from July 2009 to September 2010. In total, 2,151 cases were reported, 42% (n=895) of which were laboratory confirmed. The median age of cases was 18 years and 1,709 of 1,856 cases (92%) were unvaccinated. Many cases with complications were reported (n=305), including three with encephalitis. A total of 652 of 1,822 cases (36%) were hospitalised. Molecular characterisation revealed circulation of a limited number of measles virus genotypes (D4, D8 and B3), which is consistent with the current epidemiology of the disease in Italy. A national measles elimination plan was approved in 2003 with the aim of interrupting endemic measles transmission by 2007. Since elimination was not achieved, the target date was recently moved to 2015. The emphasis of the new elimination plan, approved in March 2011, is on strengthening surveillance, implementing evidence based-interventions to increase measles-mumps-rubella vaccine uptake in children, adolescents and young adults, and implementing communication activities related to the vaccine. The strategies proposed by the plan should be implemented fully and appropriately by all regions in order to meet the elimination goal by 2015.
Abstract 9252: Global Longitudinal Strain And Left Atrial Volume Index Predict Appropriate Implantable Cardioverter Defibrillator Therapy In Hypertrophic Cardiomyopathy Patients
Authors: Philippe J Debonnaire, Joep Thijssen, Darryl P Leong, Emer M Joyce, Jeroen J Bax, Martin J Schalij, Douwe E Atsma, Victoria Delgado, Nina Ajmone Marsan
Journal: Circulation (2012)

Introduction: Accurate predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in hypertrophic cardiomyopathy (HCM) patients have not yet been identified. Hypothesis: Left ventricular global longitudinal strain (GLS) and indexed left atrial volume (LAVI), indices of systolic and diastolic ventricular function respectively, may be predictive for appropriate ICD therapy in HCM patients. Methods: LAVI and 2-dimensional speckle tracking-derived GLS were assessed in 92 HCM patients undergoing ICD implantation. Appropriate ICD therapy was defined as occurrence of antitachycardia-pacing/shock for ventricular tachycardia/fibrillation. Results: Appropriate ICD therapy occurred in 21 (23%) patients during a median follow-up of 4.2 (1.6-7.8) years. Both LAVI and GLS showed higher accuracy for appropriate ICD therapy prediction compared to the presence of ≥1 conventional sudden cardiac death risk factor(s) [area under the ROC curve 0.76 (95%CI:0.65-0.87) and 0.65 (95%CI:0.54-0.77) versus 0.52 (95%CI: 0.43-0.58) respectively, p&lt;0.001]. In particular, the presence of LAVI ≥34 mL/m 2 or GLS ≥-14% predicted appropriate ICD therapy with 100% sensitivity. Equally important, the presence of LAVI &lt;34 mL/m 2 and GLS &lt;-14% showed a negative predictive value of 100%. Moreover, using these cut-off values, multivariate analysis revealed both LAVI (p=0.03) and GLS (p=0.04), but not the presence of any conventional sudden cardiac death risk factor, as independent predictors of appropriate ICD therapy. Likelihood ratio test (p&lt;0.001) and integrated discrimination improvement index (0.19, p&lt;0.001) showed that LAVI and GLS were of incremental value over conventional sudden cardiac death risk factor(s) to predict appropriate ICD therapy. In addition, net reclassification improvement of 0.45 indicated substantial and adequate reclassification of patients into low probability for appropriate ICD therapy including GLS and LAVI in the risk stratification model (p=0.005). Conclusion: GLS and LAVI accurately predict appropriate ICD therapy in a high-risk HCM population. In addition to conventional sudden cardiac death risk factors, both parameters may be useful to optimize criteria and timing for ICD implantation in these patients.
Abstract 4131: ICD and Shock Experience In Dialysis Patients
Authors: Anuj Shah, Sanjeev Bhavnani, Danette Guertin, Craig Coleman, Christopher Clyne, Ravi Yarlagadda, Jeffrey Kluger
Journal: Circulation (2008)

BACKGROUND: The occurrence of ventricular arrhythmias in end stage renal disease (ESRD) patients on hemodialysis (HD) is common. There are limited data on ICD patients with ESRD on HD. METHODS: We analyzed a prospectively collected database of patients with ICD implants at our institute. The patients with and without ESRD were compared for the baseline demographic variables, co-morbidities and outcomes, especially the rates of VT storm, total ICD therapies and all-cause mortality. RESULTS: There are 1438 patients with ICD implantation and follow up at our institution from April 1995 to August 2007. Of these 40 (3.3%) were on hemodialysis secondary to ESRD. The mean follow up was shorter in ESRD patients (536 ± 455 vs. 886 ± 881, p − 0.05). The ESRD group was comparable to the general ICD population for age, gender distribution, ejection fraction (mean EF 28.8 ± 15 vs. 28.9 ± 14), presence of HTN, ischemic heart disease, use of Amiodarone, beta-blockers, Digoxin and incidence of implants for primary prevention (85% vs. 74%, p - NS). The ESRD group had higher incidence of Diabetes (45% vs. 26%, p - 0.01) and lower use of Ace-inhibitors (32.5% vs. 50%, p - 0.03), biventricular pacemakers (10% vs. 24.8%). The ESRD patients had significantly worse overall mortality (52.5% vs. 23.8%, p - 0.01), one year mortality (17.5% vs. 7.4%, p - 0.029)), appropriate ICD therapies (30% vs. 17%, p - 0.03) and VT storms (17.5% vs. 5.2%, p &lt; 0.001). On Multivariate analysis, presence of ESRD was the strongest predictor of overall mortality (see table ) but not an independent predictor of one year mortality. Conclusion: In our single center experience, the dialysis patients had significantly worse outcomes than the general ICD patients, in terms of higher mortality, ICD therapies and cluster shocks. Presence of ESRD was an independent predictor of overall survival but does not predict one year mortality.
Snoring
Authors: Robert J Parker, Maxine Hardinge, Clare Jeffries
Journal: BMJ (2005)

An overweight, 49 year old male smoker attends your surgery with his wife. His snoring, which has been a running joke in the family, has become worse in the last six months, and his wife now sleeps in a separate room. When the couple stayed in a hotel recently his noise was remarked on by other guests. They want to know what they can do. Simple snoring is common in Britain (prevalence of up to 40%). You should assess the nature of the snoring, its effect on patient and partner, modifiable factors, and presence of any features indicating the more serious condition of obstructive sleep apnoea.
Il28B Genotype Is Not Associated with Advanced Hepatic Fibrosis in Chronic Hepatitis C Patients Enrolled in the Ideal Study
Authors: Alexander J. Thompson, Paul J. Clark, Jacques Fellay, Andrew J. Muir, Hans L. Tillmann, Keyur Patel, Susanna Naggie, Nezam H. Afdhal, Ira M. Jacobson, Rafael Esteban, Fred Poordad, Eric Lawitz, Jonathan McCone, Mitchell L. Shiffman, Greg Wayne Galler, John W. King, Paul Y. Kwo, Lisa M. Nyberg, Zachary Goodman, Stephanie Noviello, Navdeep Boparai, Kenneth J. Koury, Lisa Pedicone, Clifford A. Brass, Janice K. Albrecht, David B. Goldstein, John G. McHutchison, Mark S. Sulkowski
Journal: Hepatology (2010)
Abstract 2378: The MinK G38S Polymorphism Associates with Atrial Arrhythmias after Subarachnoid Hemorrhage
Authors: J M Frangiskakis, Masaki Tanabe, Marilyn Hravnak, Elizabeth A Crago, John Gorcsan, Michael B Horowitz, Barry London
Journal: Circulation (2007)

Background: Subarachnoid hemorrhage (SAH) leads to significant death and disability. Cardiac abnormalities after SAH include atrial arrhythmias (AAs). The MinK (KCNE1) G38S polymorphism has been associated with atrial fibrillation, with the G38 allele being linked to increased action potential duration in heterologous expression systems. The relationship of AAs and ion channel polymorphisms after SAH is not known. Methods: In 148 patients admitted for acute, aneurysmal SAH, EKG parameters, 24-hour Holter monitors, serum troponin (TnI), potassium (K), magnesium (Mg), and echocardiograms (ejection fraction [EF] and left atrial diameter [LA D]) were examined. MinK G38S was genotyped using fluorescent primers and analyzed with an ABI Prism 7000. Results: No patient had AAs on presentation, but AAs developed in 101 (68%) patients: SVT (95; 64%); fibrillation (9; 6%); flutter (4; 3%); idioventricular rhythm (2; 1%); and 3° block (1; 1%). AAs were not associated with PR or QTc intervals, TnI, K, Mg, EF, LA D, or stroke severity. AAs were associated with older age (58±9 vs 51±10yrs; p&lt;0.001), lower heart rate (HR; 80±10 vs 84±14bpm; p=0.02), and higher HR variability (SDNN; 97±34 vs 85±32; p=0.05). The MinK S38 allele was associated with AAs (Figure ; GS &amp; SS 70% vs GG 51%; p=0.02), but not LA D. Conclusions: Atrial arrhythmias are common following SAH and the MinK S38 allele is associated with an increased frequency of atrial arrhythmias. The SAH-induced catecholamine surge, followed by increased parasympathetic activity, may enhance the shortening of the atrial effective refractory period in patients carrying the MinK S38 allele and increase susceptibility to atrial arrhythmias.
Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT
Authors: H M Pettinati, S M Stephens, K M Willis, S E Robin
Journal: American Journal of Psychiatry (1990)

Among 48 patients with diagnoses of depression according to DSM-III, there was a significant relation between therapeutic failure of unilateral ECT, as measured by scores on the Hamilton Rating Scale for Depression, and the concomitant use of a benzodiazepine. Of the 34 patients who showed a good therapeutic response to unilateral ECT, those taking benzodiazepines had smaller changes in their Hamilton depression ratings from before treatment to after treatment and were more symptomatic at the end of the course of ECT. Thus, when patients take benzodiazepines during a course of unilateral ECT, the maximum therapeutic response may be compromised.
Ingersoll MA, Spanbroek R, Lottaz C, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010;115(3):e10–e19.
Authors: M Ingersoll, R Spanbroek, C Lottaz, E Gautier, M Frankenberger, R Hoffmann, R Lang, M Haniffa, M Collin, F Tacke, A Habenicht, L Ziegler-Heitbrock, G Randolph
Journal: Blood (2010)
Abstract 1357: PGC-1 <i>α</i> as a Novel Regulator for Angiotensin II-induced Reactive Oxygen Species Production and Hypertrophy in Vascular Smooth Muscle Cells
Authors: Shiqin Xiong, Mushtaq Ahmad, Nikolay A Patrushev, Lula Hilenski, San Martin Almeyda Alejandra, Masuko Ushio-Fukai, Wayne R Alexander
Journal: Circulation (2008)

Angiotensin II (Ang II) increases H 2 O 2 production and vascular smooth muscle cell (VSMCs) hypertrophy, in part through redox-sensitive PI3K/Akt, which is inhibited by catalase overexpression. The relevant molecular mechanism remains unclear. Peroxisome proliferator-activated receptor gamma coactivator-1 α (PGC-1 α ) is reported to protect from oxidative stress by regulating expression of antioxidant enzymes such as catalase. We thus hypothesized that PGC-1 α may be important mediator for Ang II-induced H2O2 production and vascular hypertrophy. Here we show that Ang II stimulation increases serine phosphorylation of PGC-1 α (2.2 folds) with a peak at 15 min, which is inhibited by LY294002, a specific PI3 kinase inhibitor (98% decrease), and by Akt inhibitor-2/Triciribine (95% decrease). Ang II promotes PGC-1 α phosphorylation mainly at Ser 570 in an Akt-dependent manner. Ang II significantly suppresses Gal4-fused PGC-1 α transcriptional activity in a dose dependent manner, which is partially reversed by PI3K/Akt inhibition. Chromatin immunoprecipitation (ChIP) assay shows that PGC-1 α associates with the catalase promoter and this association is blocked by Ang II in a PI3K/Akt-dependent manner. Consistent with these results, Ang II stimulation time-dependently decreases endogenous catalase expression at both messenger RNA and protein levels. Ang II-induced downregulation of catalase at protein level at 24 hrs is prevented by Akt inhibitor (86%) and by overexpression of PGC-1 α S570A, an Akt phosphorylation site mutant, (75%). Moreover, overexpression of PGC-1 α S570A significantly inhibits Ang II-induced increase in H2O2 production (&gt;80%) and leucine incorporation (&gt;90%) as measured at 12 and 24 hrs, respectively. In summary, Akt-dependent serine phosphorylation of PGC-1 α by Ang II plays an important role for Ang II-induced downregulation of catalase, thereby increasing H2O2 production, which may contribute to ROS-dependent VSMC hypertrophy. These findings provide insight into a novel mechanisms by which Ang II promotes long-term H2O2 production to increase oxidative stress via targeting PGC-1alpha, and mediates metabolic abnormalities.
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas: A pilot study
Authors: S. B. Jeon, J. G. Kim, J. H. Baek, D. H. Kim, S. K. Sohn, J.-J. Lee, I.-J. Chung, H.-J. Kim, W.-S. Lee, C.-H. Sohn
Journal: Journal of Clinical Oncology (2005)

6638 Background: The present study was conducted to evaluate the safety and efficacy of CHOP plus etoposide and gemcitabine as front-line chemotherapy for patients with peripheral T cell lymphomas. Methods: Patients with newly diagnosed peripheral T cell lymphomas except cutaneous T cell lymphoma and ALK positive anaplastic large cell lymphoma were enrolled. Treatment consisted of classical CHOP plus etoposide 100 mg/m2 intravenously (i.v.) on day 1 and gemcitabine 600 mg/m2 i.v. on day 1 in a 3 weeks interval. Results: Twenty-two patients were enrolled in onto the currentthis study. The median age was 57.5 years (range, 20–68 years). Histological subtypes were as follows: peripheral T cell unspecified (n=12), extranodal NK/T cell, nasal type (n=6), angioimmunoblastic T cell (n=2), ALK negative anaplastic large cell (n=2). Fourteen complete responses (CR; 63.6%) and 3 partial responses (PR; 13.6%) were confirmed, giving an overall response rate of 77.3% (95% CI; 58.3%–96.3%). Grade 4 neutropenia occurred in 15 patients (68.2%), and febrile neutropenia was observed in 4 patients (18.2%). However, there was no treatment-related death. The common non-hematological toxicities were nausea (grade 1/2, 63.6%) and stomatitis (grade 1/2, 31.8%). Median survival has not yet been reached, while median event free survival was 172.5 days at a median follow-up duration of 222 days (range, 88–522 days). Estimated overall survival at 1-year was 56.3 ± 14.7%. Conclusions: The CHOP-EG regimen was found to be well-tolerated and effective in patients with peripheral T cell lymphomas. A phase II study is currently ongoing, and the results will be presented at the meeting. No significant financial relationships to disclose.